Amine derivatives and pharmaceutical compositions containing them

US4279911A · kind A · utility

Assignee

• Glaxo Group Limited · GB

Inventors

• Michael Martin-Smith · Hertford, GB
• Barry J. Price · London, GB
• John Bradshaw · Solon, US
• John W. Clitherow · Sawbridgeworth, GB

Key dates

• Filing date: Jun 6, 1980
• Grant date: Jul 21, 1981
• Expiry date: Jun 6, 2000

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D333/20
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, N-oxides, hydrates and bioprecursors thereof, in which Y represents .dbd.O, .dbd.S, .dbd.CHNO.sub.2 or .dbd.NR.sub.3 where R.sub.3 represents hydrogen, nitro, cyano, lower alkyl, aryl, lower alkylsulphonyl or arylsulphonyl; R.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen lower alkyl, cycloalkyl, lower alkenyl, aralkyl, hydroxy, lower trifluoroalkyl, lower alkyl substituted by hydroxy, lower alkoxy, amine, lower alkylamino or dialkylamino, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring which may contain other heteroatoms or the group ##STR2## where R.sub.4 represents hydrogen or lower alkyl; PA0 Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, or a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions; PA0 X represents --CH.sub.2 --, --O-- or --S--; PA0 n represents zero, 1 or 2; PA0 m represents 2, 3 or 4; PA0 Alk re…